Business · 12/07/2019Updated: 10/17/2026 · 1 min read
FDA Cancels Public Workshop on Antiviral Drugs for Adenoviral Infection in Immunocompromised Patients
Summary
The US Food and Drug Administration (FDA) has cancelled a public workshop previously scheduled for August 8, 2019, due to unforeseen changes in the adenovirus drug development landscape, which was announced in the Federal Register on May 2, 2019.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →